1.Critically assess the need for antiviral therapy: It is not advisable to start antiviral therapy for patients with mild inflammatory lesions in the liver and difficulty in obtaining a sustained response: e.g., normal ALT, HBeAg-positive immune-tolerant stage (that is, hepatitis B carriers as we often call them), especially when these patients are years old. 2, the choice of antiviral drugs: start treatment with priority recommended ETV (entecavir) and TDF (tenofovir), the first-line antiviral drugs. 3. Regular HBV DNA testing (3 months) during treatment to detect primary non-response or virologic breakthrough in a timely manner. Once virologic breakthrough occurs, testing for genotypic resistance should be performed and salvage therapy should be given as early as possible.